As of November 6, 2026, 9 holders' latest Schedule 13D or 13G filings report owning 5% or more of InspireMD, Inc. The largest reported stake is Marshall Wace, Llp's, at 9.99%. 18 filings are on record since August 6, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like InspireMD, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Velan Capital Master Fund LP · Percent: 4.99% · SCHEDULE 13G/A
- · Holder: Nantahala Capital Management, LLC · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: Marvin Slosman · Percent: 5.18% · SCHEDULE 13D
- · Holder: Orbimed Advisors LLC · Percent: 7.4% · SCHEDULE 13G
- · Holder: Rosalind Advisors, Inc. · Percent: 9.2% · SCHEDULE 13G/A
InspireMD, Inc. has 18 Schedule 13D or 13G filings on record since 2025-08-06. 9 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Marshall Wace, Llp | 9.99% | 28,103,699 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Nantahala Capital Management, LLC | 9.99% | 4,819,647 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Rosalind Advisors, Inc. | 9.2% | 10,987,104 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| 8.6% | 3,614,731 | SCHEDULE 13D, 2025-10-29 | 2025-06-26 | |
| Aberdeen Group plc | 7.49% | 3,173,364 | SCHEDULE 13G/A, 2026-02-02 | 2025-12-31 |
| Orbimed Advisors LLC | 7.4% | 3,133,405 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Parkman Healthcare Partners LLC | 5.8% | 2,440,633 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Nantahala Capital Partners Limited Partnership | 5.68% | 2,418,016 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| 5.18% | 2,556,760 | SCHEDULE 13D, 2026-04-24 | 2026-01-22 | |
| Velan Capital Master Fund LP | 4.99% | 2,347,779 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| 3.5% | 1,484,505 | SCHEDULE 13D/A, 2025-10-29 | 2025-06-26 |
Holding shares or following this stake? See who's behind InspireMD, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on InspireMD, Inc. and the records around it.
InspireMD, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Velan Capital Master Fund LP also filed stake reports on 2 other companies: Edesa Biotech, Inc. (Aug 2026), Jasper Therapeutics, Inc. (Aug 2026)
- NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP also filed stake reports on 6 other companies: FEMASYS INC. (Aug 2026), AZITRA, INC. (Aug 2026), ABEONA THERAPEUTICS INC. (May 2026)
- Rosalind Advisors, Inc. also filed stake reports on 11 other companies: DELCATH SYSTEMS, INC. (Oct 2026), FEMASYS INC (Aug 2026), FENNEC PHARMACEUTICALS INC. (Aug 2026)
Watch InspireMD, Inc.
Get an email when InspireMD, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on InspireMD, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on InspireMD, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on InspireMD, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
21 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Michael A. Lawless
Item 3 above is hereby incorporated into this Item 4 by reference. The Reporting Person serves as an executive officer of the Issuer and, in such capacity, may be involved in reviewing transactions involving the Issuer and may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer as compensation from the Issuer, by purchase or otherwise, including, including, but not limited to, awards of restricted Shares, options to purchase Shares, and restricted stock units for Shares, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions (which may be with the Issuer or with third parties) on such terms and at …The first part of Item 4 of the SCHEDULE 13D filed 2025-10-29; the filing has the rest
Craig Shore
Item 3 above is hereby incorporated into this Item 4 by reference. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions on such terms and at such times as the Reporting Person may deem advisable.Item 4 of the SCHEDULE 13D/A filed 2025-10-29
Marvin Slosman
Item 3 above is hereby incorporated into this Item 4 by reference. The Reporting Person serves as an executive officer of the Issuer and, in such capacity, may be involved in reviewing transactions involving the Issuer and may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. As of the date hereof, the Reporting Person in his individual capacity does not have any present plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D. The Reporting Person may, at any time and from time to time, (i) review or reconsider his position in the Issuer or change his purpose or formulate plans or proposals with respect thereto or (ii) propose or consider one or more of the actions described in clauses (a) through (j) of Item 4 to Schedule 13D. From time to time, the Reporting Person may also acquire beneficial ownership of additional Shares or other securities of the Issuer as compensation from the Issuer, by purchase or otherwise, including, including, but not limited to, awards of restricted Shares, options to purchase Shares, and restricted stock units for Shares, or dispose of some or all of the Shares beneficially owned by the Reporting Person in the open market or in privately negotiated transactions (which may be with the Issuer or with third parties) on such terms and at …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-24; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-06 | Velan Capital Master Fund LP | 5.1% | SCHEDULE 13G |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.4% | SCHEDULE 13G/A |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.4% | SCHEDULE 13G/A |
| 2025-08-11 | Rosalind Advisors, Inc. | 9.9% | SCHEDULE 13G/A |
| 2025-10-29 | Michael A. Lawless | 8.6% | SCHEDULE 13D |
| 2025-10-29 | Craig Shore | 3.5% | SCHEDULE 13D/A |
| 2025-11-07 | Aberdeen Group plc | 5.95% | SCHEDULE 13G |
| 2025-11-14 | Marshall Wace, Llp | 9.99% | SCHEDULE 13G/A |
| 2025-11-14 | Parkman Healthcare Partners LLC | 5.8% | SCHEDULE 13G |
| 2025-11-14 | OrbiMed Advisors LLC | 4.1% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Partners Limited Partnership | 5.68% | SCHEDULE 13G/A |
| 2025-11-14 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-02 | Aberdeen Group plc | 7.49% | SCHEDULE 13G/A |
| 2026-02-11 | Rosalind Advisors, Inc. | 9.2% | SCHEDULE 13G/A |
| 2026-02-17 | Orbimed Advisors LLC | 7.4% | SCHEDULE 13G |
| 2026-04-24 | Marvin Slosman | 5.18% | SCHEDULE 13D |
| 2026-05-15 | Velan Capital Master Fund LP | 4.99% | SCHEDULE 13G/A |
| 2026-05-15 | Nantahala Capital Management, LLC | 9.99% | SCHEDULE 13G/A |
Questions about who owns InspireMD, Inc.
Who owns InspireMD, Inc.?
On this page, 9 holders' latest ownership filings report 5% or more of InspireMD, Inc.: Marshall Wace, Llp (9.99%, Schedule 13G/A, filed 2025-11-14), Nantahala Capital Management, LLC (9.99%, Schedule 13G/A, filed 2026-05-15), Rosalind Advisors, Inc. (9.2%, Schedule 13G/A, filed 2026-02-11), Michael A. Lawless (8.6%, Schedule 13D, filed 2025-10-29) and Aberdeen Group plc (7.49%, Schedule 13G/A, filed 2026-02-02); 4 more are listed above.
Who are the largest shareholders of InspireMD, Inc.?
By the share each holder's latest filing reports, the largest holders of InspireMD, Inc. on this page are Marshall Wace, Llp (9.99%), Nantahala Capital Management, LLC (9.99%) and Rosalind Advisors, Inc. (9.2%).
When did Marshall Wace, Llp buy into InspireMD, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Marshall Wace, Llp on this page is the Schedule 13G/A, filed 2025-11-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for InspireMD, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 2, 2026 | Leadership change: Raymond W. Cohen departs, Director | — | Leadership changes | Source |
| May 22, 2026 | Leadership change: Paul Stuka departs, Director | — | Leadership changes | Source |
| August 4, 2025 | Form D, private offering | $40.06M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for InspireMD, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.